Company Profile

TYDOCK PHARMA S.r.l. is a chemistry-driven research-intensive biostart-up company born in 2006 which was selected among the 15 Most Established Italian Spin-off by the Italian Trade Commission in New York  [Report ICE 2009].
The mission of TYDOCKPHARMA S.r.l. focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on infection and more recently on cancer diseases.
The Company, a Research and Technology Transfer Center, is recipient of research grants from the European Commission (FP7) (MM4TB, More Medicines for tuberculosis, 2011-2015) and the EUROTRANSBIO project (EUROpean network of TRANSnational collaborative Research and Development for SME projects in the field of BIOtechnology, www.eurotransbio.eu, SMART Specie Specificity Management in Resistant infectious diseases targeting Thymidylate synthase).  2008-2010.
 
TYDOCK PHARMA is involved in different projects to expand its capabilities through technology transfer of basic research-to industrial application of innovative technologies.